logo
Wrong email address or username
Wrong email address or username
Incorrect verification code
back to top
Search tags: Drugs
Load new posts () and activity
Like Reblog Comment
text 2018-06-14 12:07
Hepatocellular Carcinoma Drugs Market - Global Industry Insights, 2026

Hepatocellular carcinoma (HCC) is a major type of primary liver cancer that arises from the liver cells or hepatocytes. The disease is found to occur mainly in patients with hepatitis B, hepatitis C, cirrhosis, obesity, and diabetes. Diagnosis of hepatocellular carcinoma is mainly done by imaging tests such as ultrasound, MRI, CT scan, and liver biopsy. Treatment for hepatocellular carcinoma mainly includes radiation therapy, ablation therapy in addition to chemotherapy and targeted drug therapy.

 

Request Sample Copy of this Business Report @ https://www.coherentmarketinsights.com/insight/request-sample/1596

 

A majority of the HCC patients are diagnosed at the end-stage of liver dysfunction. Due to poor prognosis of the condition, mortality rate is approximately the same as the incidence rate. Therefore, early detection of the cancer is an important parameter to improve the survival of affected patients, thus aiding in growth of the global hepatocellular carcinoma drugs market.

 

Increasing incidence of global hepatocellular carcinoma cases is a major factor augmenting market growth. According to the research by International Journal of Cancer Research and Treatment, 2014, HCC is the sixth most common type of cancer worldwide and third most common cause of death worldwide, fifth for men and eighth for women. The disease accounts for more than 5% of all cancers and for 80-90% of primary liver cancers. Also, according to the Addis Ababa University, 2017, hepatocellular carcinoma (HCC) accounted to 854,000 new cases of liver cancer and 810,000 related deaths in 2015. Furthermore, increasing incidence and mortality of hepatocellular carcinoma is attributed to the emergence of new risk factors such as hepatitis B and C viral infections, metabolic disorders such as diabetes and non-alcoholic fatty liver disease, and exposure to toxins such as alcohol and aflatoxin.

 

Click To Continue Reading on Hepatocellular Carcinoma Drugs Market

 

About Coherent Market Insights:

 

 

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

 

Contact Us:

 

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702

Email: sales@coherentmarketinsights.com

Visit our news Website: https://www.coherenttimes.org/



Like Reblog Comment
text 2018-05-30 13:16
Cervical Ripening Drugs Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012 to 2016 and Forecast 2017 to 2023

Cervical Ripening Drugs Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012 to 2016 and Forecast 2017 to 2023

 

Market Outline: Cervical Ripening Drugs Market

Cervical ripening is defined as the softening of cervix prior to onset of labor contractions and it is necessary for the cervical dilation and passage of fetus. Cervix softens, thins, dilates, and relaxes in response to the uterine contractions and allows the cervix to easily pass over the fetal part during labor. Cervical ripening Drugs are used before the induction of labor for the dilatation of cervix. The ripening of cervix is associated with the reduced collagen fiber strength, decrease in collagen fiber alignment, and diminished the tensile strength of extracellular cervical matrix. The common techniques used for the cervical ripening are mechanical interventions such as insertion of cervical catheters and dilators and application of cervical ripening agents such as prostaglandins.

 

Market Dynamics: Cervical Ripening Drugs Market

Growing usage of cervical ripening Drugs before the induction of labor, rise in R&D activities for the innovation of newer Drugs, increase in awareness about cervical ripening Drugs in developed and developing countries, low cost of Drugs, and government initiations for improving the baby deliveries are anticipated to fuel the cervical ripening Drugs market over the forecast period. However, stringent regulatory policies for product approval, adverse effects associated with the cervical ripening Drugs, and alternative procedures for the childbirth are expected to hinder the growth of surgical ripening Drugs market over the forecast timeframe.

 

A sample of this report is available upon request @

 https://www.precisionbusinessinsights.com/market-reports/cervical-ripening-drugs-market/#ulp-4H8Z4LpNMLEuOnnx

 

 

Market Scope: Cervical Ripening Drugs Market

Cervical ripening Drugs market is segmented on the basis of drug type, route of administration, distribution channel, and region

Based on the drug type, market is segmented into the following:

  • Prostaglandins
  • Oxytocin
  • Progesterone Receptor Antagonists
  • Relaxin
  • Estrogen
  • Others

Based on the route of administration, market is segmented into the following:

  • Oral
  • Intravenous
  • Vaginal

Based on the distribution channel, market is segmented into the following:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

 

 

To view TOC of this report is available upon request @

 https://www.precisionbusinessinsights.com/market-reports/cervical-ripening-drugs-market/#ulp-c654SbFYO64MsOhu

 

 

Market Summary: Cervical Ripening Drugs Market

Cervical ripening Drugs market is projected to grow at a significant rate with increase in the usage of cervical ripening Drugs prior to the induction of labor. Moreover, acquisitions and mergers, product approvals, and product launchings are the key strategies adopted by market players to generate increased revenue in cervical ripening Drugs market. For instance, in February 2012, Ferring Pharmaceuticals acquired Cytokine PharmaSciences Inc. and the acquisition includes manufacturing assets of Cervidil (Dinoprostone) in U.S. and Canada.

 

Regional Analysis:  Cervical Ripening Drugs Market

Geographically, global cervical ripening Drugs market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America cervical ripening Drugs market growth driven by increase in the R&D for the innovation of newer Drugs and high awareness about the cervical ripening Drugs among the physicians. Europe cervical ripening Drugs market has a lucrative growth owing to high adoption of cervical ripening Drugs, launching of newer Drugs by the market players. Asia Pacific cervical ripening Drugs market has significant share owing to rise in number of female population, government initiations for the baby birth, and increase in the using of cervical ripening Drugs before the induction of labor are propel the market. Middle East and Africa cervical ripening Drugs market has a prominent share owing to increase in the number of births and rise in awareness about the cervical ripening Drugs are in the region.

 

Competition Assessment: Cervical Ripening Drugs Market  

Some of the players in the global cervical ripening Drugs market include:

  • Ferring B.V. (Switzerland)
  • Azanta A/S (Denmark)
  • Novartis AG (Switzerland)
  • GlaxoSmithKline plc (U.K.)
  • AstraZeneca plc (U.K.)
  • Pfizer, Inc. (U.S.)
  • Bayer AG (Germany)

 

Need more information about this report @

 https://www.precisionbusinessinsights.com/market-reports/cervical-ripening-drugs-market/#ulp-14mlyhjMGhVjZqa3

 

 

Notable Market Developments: Cervical Ripening Drugs Market

  • In February 2016, Azanta A/S filed marketing authorization application in Nordic countries for Angusta (Misoprostol), which is indicated in induction of labor

 

Key Features of the Report:

  • The report provides granular level information about the market size, regional market share, historic market (2012 to 2016) and forecast (2017 to 2023)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

 

 

Get access to full summary @

https://www.precisionbusinessinsights.com/market-reports/cervical-ripening-drugs-market/

 

About Precision Business Insights

 

Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.

 

Precision Business Insights mission is to provide high-quality market research reports and generate key insights to our clients. PBI’s approachable strategies are to help clients to make key decisions for business growth.

 

Precision Business Insights vision is to become most valued partner to fortune 500 companies by providing agile, accurate, and actionable market insights

 

Contact to Precision Business Insights,

 

Kemp House,

 

152 – 160 City Road,

 

London EC1V 2NX

 

Email: sales@precisionbusinessinsights.com

 

Toll Free (US): +1-866-598-1553

Website @ https://www.precisionbusinessinsights.com

 

Like Reblog Comment
text 2018-05-30 12:21
Celiac Disease Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018

Celiac Disease Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018

 

Celiac Disease Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018

 

Celiac Disease Pipeline Drugs Assessment

 

Overview:

Celiac Diseaseis a genetic autoimmune disease. It is caused due to the consumption of protein called gluten, which is found in barley, wheat,and rye. It enables damage the finger-like villi of small intestine and body will be unable to absorb nutrients into thebloodstream that leads to malnutrition. Symptoms of celiac disease include food allergy, watery and itchy eyes, difficulty in breathing, nausea, abdominal pain, mouth ulcers.

Celiac disease is diagnosed by serology tests and genetic tests. Treatment includes strict gluten-free diet. There are no FDA approved drugs to treat celiac disease.

 

A sample of this report is available upon request @

https://www.precisionbusinessinsights.com/market-reports/celiac-disease-pipeline-drugs-assessment/#ulp-4H8Z4LpNMLEuOnnx

 

Segmentation:

By Drugs, Celiac Disease pipeline drugs are segmented as:

  • Larazotide
  • Pancrelipase
  • Rifaximin
  • Triamcinolone
  • Bupivacaine

By Route of Administration, Celiac Disease pipeline drugs are segmented as:

  • Oral
  • Parenteral

By Trial Phase, Celiac Diseasepipeline drugs are segmented as:

  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3
  • Phase 4

By Company, Celiac Diseasepipeline drugs are segmented as:

  • AMYRA Biotech AG (Switzerland)
  • Avaxia Biologics, Inc. (U.S.)
  • Calypso Biotech SA (Switzerland)
  • Provid Pharmaceuticals Inc. (U.S.)
  • Sitari Pharmaceuticals (U.S.)
  • Cour Pharmaceuticals (U.S.)
  • Glenmark Pharmaceuticals Ltd. (India)
  • Innovate Biopharmaceuticals (U.S.)
  • Others

 

To view TOC of this report is available upon request @

https://www.precisionbusinessinsights.com/market-reports/celiac-disease-pipeline-drugs-assessment/#ulp-c654SbFYO64MsOhu

 

 

 

Space Analysis:

  • In November 2017, ImmusanT, Inc.raised $40 million Series C equity financing from ARCH Venture Partners and Vatera Healthcare Partners to proceedPhase II clinical trial of escalating doses of Nexvax2 in celiac patients who possess the human leukocyte antigen DQ2.5 (HLA-DQ2.5) immune recognition gene.
  • In February 2016, Innovate Biopharmaceuticals Inc., completed an agreement to license Alba Therapeutics assets relating to larazotide acetate, a tight junction regulator, progressing toward Phase 3 clinical trials for the treatment of celiac disease.
  • In December 2015, Takeda Pharmaceutical Company Limited and Cour Pharmaceutical Development Company, Inc. entered into a partnership to research and develop novel immune modulating therapies for the potential treatment of celiac disease
  • In March 2015, Falk Pharma and Zedira entered into a collaboration to perform Phase 1 clinical trials of ED1227, a direct-acting inhibitor of tissue transglutaminase. The small molecule targets the dysregulated transglutaminase within the small intestine in order to dampen the immune response to gluten which drives the celiac disease process.

 

Report Description:

Celiac Disease Pipeline Drugs Assessment report studies the various therapeutics under clinical development for Celiac Disease treatment along with targets for various drug candidate. The report provides plethora of information pertaining to trail phases, companies involved in the Celiac Disease pipeline drugs development. This report studies the dynamics of the Celiac Disease Pipeline Drugs i.e. drivers, challenges and opportunities which are significantly impacting the product development. The report provides various information pertaining the clinical trials such as designation, grants, patents, and technology among others. Moreover, the report on Celiac Disease pipeline drugs assessment comprehensively presents the geographic location, trial status information along with key players involved in the therapeutics development.

 

Need more information about this report @

https://www.precisionbusinessinsights.com/market-reports/celiac-disease-pipeline-drugs-assessment/#ulp-14mlyhjMGhVjZqa3

 

 

 

Key Features of the Report:

  • Provides the information related to universities and research institutes working in the therapeutics development
  • Report comprehensively covers the all active and discontinued studies
  • Studies the entire pipeline with special emphasis on companies actively involved in the therapeutics development
  • Presents the prominent targets for drug development in each stage of clinical trial
  • Provides the in-depth analysis on each drug candidates in the clinical trial phases

 

 

Get access to full summary @

https://www.precisionbusinessinsights.com/market-reports/celiac-disease-pipeline-drugs-assessment/

About Precision Business Insights

 

Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.

 

Contact to Precision Business Insights,

 

Kemp House,

152 – 160 City Road,

London EC1V 2NX

 

Email: sales@precisionbusinessinsights.com

 

Toll Free (US): +1-866-598-1553

Website @ https://www.precisionbusinessinsights.com

 

 

Like Reblog Comment
text 2018-05-30 07:42
Beta-Thalassemia Disease Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018

 

Beta-Thalassemia Disease Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018

 

Overview:

Beta-Thalassemia is an inherited blood disorder characterized by decreased levels of functional hemoglobin, which is the iron containing protein present in red blood cells that carries oxygen to the cells throughout the body. People with Beta-Thalassemia will be suffering from lack of oxygen supply in body and also shortage of red blood cells and will be at the increased risk of developing abnormal blood clots.

Symptoms of Beta-Thalassemia includes pale skin, jaundice, enlarged spleen, liver and heart, delayed puberty. Beta-Thalassemia can be diagnosed by molecular and genetic tests, blood tests etc. Treatment of Beta-Thalassemia includes frequent blood transfusions, bone marrow transplant, surgery to remove spleen or gallbladder and medications.

 

A sample of this report is available upon request @

https://www.precisionbusinessinsights.com/market-reports/beta-thalassemia-disease-pipeline-drugs-assessment/#ulp-4H8Z4LpNMLEuOnnx

 

Segmentation:

By Trial Phase, Beta-Thalassemiapipeline drugs are segmented as:

  • Preclinical Trials
  • Phase 1
  • Phase 2
  • Phase 3
  • Phase 4

By Company, Beta-Thalassemiapipeline drugs are segmented as:

  • Celgene Pharmaceuticals
  • bluebird bio.Inc
  • GlaxoSmithKline
  • Acceleron Pharma, Inc.
  • Sanofi
  • Novartis
  • HemaQuest Pharmaceuticals Inc.
  • Hoffmann-La Roche
  • FerroKinBioSciences, Inc.
  • Others

By Drugs, Beta-Thalassemia pipeline drugs are segmented as:

  • LentiGlobin
  • Deferitrin
  • Desferoxamine
  • Bitopertin
  • Deferasirox
  • Luspatercept
  • Zoledronic acid
  • Ambrisentan
  • Others

By Type of Condition, Beta-Thalassemia pipeline drugs are segmented as:

  • Thalassemia Major (Cooley’s anemia)
  • Thalassemia Intermedia

By Route of Administration, Beta-Thalassemiapipeline drugs are segmented as:

  • Oral
  • Parenteral

 

To view TOC of this report is available upon request @

https://www.precisionbusinessinsights.com/market-reports/beta-thalassemia-disease-pipeline-drugs-assessment/#ulp-c654SbFYO64MsOhu

 

 

Space Analysis:

  • In October 2017, Sangamo Therapeutics and Bioverativreceived U.S.FDA IND acceptance to begin human clinical studies of ST-400, a gene-edited cell therapy candidate for people with transfusion-dependent beta-thalassemia.
  • In September 2016, bluebird bio, Inc. commenced a phase III global multi center study of its HGB-207  in patients with transfusion-dependent beta-thalassemia with non-β00genotypes
  • In May 2015, Luspatercept of Celgene Corporation and Acceleron Pharma Inc. was granted Fast track designations by U.S. FDA for two separate indications, for the treatment of patients with transfusion dependent beta-thalassemia and patients with non-transfusion dependent beta-thalassemia. Luspatercept is a modified activin receptor type IIB fusion protein that acts as a ligand trap for members of the Transforming Growth Factor-Beta (TGF-beta) superfamily involved in the late stages of erythropoiesis (red blood cell production). Luspatercept regulates late-stage erythrocyte (red blood cell) precursor cell differentiation and maturation

 

Report Description:

Beta-ThalassemiaDisease Pipeline Drugs Assessment report studies the various therapeutics under clinical development for Beta-Thalassemia treatment along with targets for various drug candidate. The report provides plethora of information pertaining to trail phases, companies involved in the Beta-Thalassemia disease pipeline drugs development. This report studies the dynamics of the Beta-Thalassemia Disease Pipeline Drugs i.e. drivers, challenges and opportunities which are significantly impacting the product development. The report provides various information pertaining the clinical trials such as designation, grants, patents, and technology among others. Moreover, the report on Beta-Thalassemia disease pipeline drugs assessment comprehensively presents the geographic location, trial status information along with key players involved in the therapeutics development.

 

Need more information about this report @

https://www.precisionbusinessinsights.com/market-reports/beta-thalassemia-disease-pipeline-drugs-assessment/#ulp-14mlyhjMGhVjZqa3

 

Key Features of the Report:

  • Provides the information related to universities and research institutes working in the therapeutics development
  • Report comprehensively covers the all active and discontinued studies
  • Studies the entire pipeline with special emphasis on companies actively involved in the therapeutics development
  • Presents the prominent targets for drug development in each stage of clinical trial
  • Provides the in-depth analysis on the each drug candidates in the clinical trial phases

 

Get access to full summary @

https://www.precisionbusinessinsights.com/market-reports/beta-thalassemia-disease-pipeline-drugs-assessment/

About Precision Business Insights

 

Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.

 

Contact to Precision Business Insights,

 

Kemp House,

152 – 160 City Road,

London EC1V 2NX

 

Email: sales@precisionbusinessinsights.com

 

Toll Free (US): +1-866-598-1553

Website @ https://www.precisionbusinessinsights.com

 

Like Reblog Comment
text 2018-05-30 06:47
Atopic Dermatitis Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018

Atopic Dermatitis Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018

Atopic Dermatitis Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018

 

Atopic Dermatitis Pipeline Drugs Assessment

 

Overview:

Atopic dermatitis is a chronic, pruritic inflammatory skin disease with unknown origin. It generally occurs in children but affects a substantial number of adults.Symptoms include dry skin, itching, red to brownish-grey patches especially on hands, neck, upper feet, legs, inside the bend of elbows, knees and other parts of the body.

Atopic dermatitis generally examined through the physical examination. No cure has been found for atopic dermatitis, but the treatment is given for relieving the symptoms. Treatment may include topical applications to relieve the itching, oral drugs to control the inflammation and drugs for infection control.Food and Drug Administration (FDA) has recently approved a new, injectable monoclonal antibody, dupilumab for the treatment of severe atopic dermatitis.

 

A sample of this report is available upon request @

https://www.precisionbusinessinsights.com/market-reports/atopic-dermatitis-pipeline-drugs-assessment/#ulp-4H8Z4LpNMLEuOnnx

 

Segmentation:

By route of administration, atopic dermatitis pipeline drugs are segmented into

  • Oral
  • Topical
  • Parenteral

By Trial Phase, Atopic Dermatitis pipeline drugs are segmented as:

  • Preclinical Trials
  • Phase 1
  • Phase 2
  • Phase 3

By company, Atopic Dermatitis pipeline drugs are segmented into

  • AbbVie Inc. (U.S.)
  • Sterna Biologicals GmbH & Co. KG (Germany)
  • Santalis Pharmaceuticals, Inc. (U.S.)
  • MedImmune LLC (U.S.)
  • Eli Lilly and Company (U.S.)
  • Regeneron Pharmaceutical (U.S.)
  • Sienna Biopharmaceuticals (U.S.)
  • Others

 

To view TOC of this report is available upon request @

https://www.precisionbusinessinsights.com/market-reports/atopic-dermatitis-pipeline-drugs-assessment/#ulp-c654SbFYO64MsOhu

 

 

Space Analysis:

Currently, there is no availability of effective treatments to treat atopic dermatitis. Most of the drugs are used to relieve the symptoms. Two Janus kinase inhibitors approved for rheumatoid arthritis and myelodysplasia. One of these drugs isstudied for atopic dermatitis but drug is not actively developed now. Many Janus kinase inhibitors are in clinical trial stages for treatment of atopic dermatitis.

  • In March 2017, LEO Pharma announced positive results from a Phase 2b dose-ranging efficacy and safety study of tralokinumab in adult patients with moderate to severe atopic dermatitis (AD).
  • In January 2017, AbbVie announced that the U.S. FDA granted Breakthrough Therapy Designation for the investigational, once-daily oral JAK1-selective inhibitor upadacitinib (ABT-494) in adult patients with moderate to severe atopic dermatitis who are candidates for systemic therapy.

 

Need more information about this report @

https://www.precisionbusinessinsights.com/market-reports/atopic-dermatitis-pipeline-drugs-assessment/#ulp-14mlyhjMGhVjZqa3

 

Report Description:

Atopic Dermatitis Disease Pipeline Drugs Assessment report studies the various therapeutics under clinical development for Atopic Dermatitis treatment along with targets for various drug candidate. The report provides plethora of information pertaining to trail phases, companies involved in the Atopic Dermatitis disease pipeline drugs development. This report studies the dynamics of the Atopic Dermatitis Disease Pipeline Drugs i.e. drivers, challenges, and opportunities which are significantly impacting the product development. The report provides various information pertaining the clinical trials such as designation, grants, patents, and technology among others. Moreover, the report on Atopic Dermatitis disease pipeline drugs assessment comprehensively presents the geographic location, trial status information along with key players involved in the therapeutics development.

 

Key Features of the Report:

  • Provides the information related to universities and research institutes working in the therapeutics development
  • Report comprehensively covers the all active and discontinued studies
  • Studies the entire pipeline with special emphasis on companies actively involved in the therapeutics development
  • Presents the prominent targets for drug development in each stage of clinical trial
  • Provides the in-depth analysis of each drug candidates in the clinical trial phases

 

 

Get access to full summary @

https://www.precisionbusinessinsights.com/market-reports/atopic-dermatitis-pipeline-drugs-assessment/

About Precision Business Insights

 

Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.

 

Contact to Precision Business Insights,

 

Kemp House,

152 – 160 City Road,

London EC1V 2NX

 

Email: sales@precisionbusinessinsights.com

 

Toll Free (US): +1-866-598-1553

Website @ https://www.precisionbusinessinsights.com

More posts
Your Dashboard view:
Need help?